Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- LDP Committee Calls for Setting Up Asian Hub of PMDA
May 18, 2023
- Industry Associations Stress Special Cost Structure of SaMD in Chuikyo Hearing
May 18, 2023
- Market Expansion Re-Pricing to Hit Tarlige, Entresto, Verzenio; Spillover to 2 Other Meds
May 18, 2023
- Deregulation Panel Eyes Use of Medical Data “Without Patient Consent”
May 17, 2023
- LDP Project Team to Finalize Pharma Policy Proposal for Honebuto by May-End, Submit It to Prime Minister
May 17, 2023
- Create Command Tower to Integrate Innovation Support and Drug Pricing Policy: LDP Project Chief
May 17, 2023
- Chuikyo OKs Listing of Omvoh, Entyvio SC, Besremi, and More; Biggest Sales Outlook for Lilly Drug
May 17, 2023
- Novo’s Obesity Drug Wegovy Skips May Listing, Sobi’s Empaveli Too
May 17, 2023
- Cancer Meds from Servier, Taiho, Pfizer’s AA Drug Up for Panel Review on May 29
May 16, 2023
- MHLW Issues ICH E19-Based Guideline on Selective Approach to Safety Data Collection in Clinical Trials
May 16, 2023
- 68.3% of Public Comments Supported Mefeego Approval: MHLW
May 16, 2023
- G7 Health Chiefs Vow to Spur Antibiotic and Dementia Drug Development, Access to Vaccines
May 15, 2023
- Gene Therapy Luxturna Up for MHLW Panel Review on May 26
May 15, 2023
- Komeito Lawmakers Propose Review of Off-Year Re-Pricing, Correction of Multi-Product Small-Lot Generic Production
May 12, 2023
- MOF Continues to See Macroeconomic Indexing Reasonable: Panel Meeting
May 12, 2023
- LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
- Nonpartisan Lawmaker League OKs Dementia Bill, Eyes Enactment in Current Diet
May 11, 2023
- No Additional Safety Measures Needed at this Time for Xocova: Panel
May 11, 2023
- Label Revisions Ordered for 32 Hypertension Meds to Caution against Fetal Risks
May 10, 2023
- LDP’s Life Science League Submits Proposal; Ex-Minister Urges Price Debate from Industrial Policy Perspective
May 10, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…